ImmunityBio, Inc.
IBRX
$2.13
$0.010.47%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 20.28% | 60.04% | |||
| Total Other Revenue | 6,925.00% | -50.00% | |||
| Total Revenue | 21.33% | 59.99% | |||
| Cost of Revenue | 30.15% | 134.48% | |||
| Gross Profit | 21.28% | 59.72% | |||
| SG&A Expenses | -13.94% | 29.07% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -10.25% | 20.71% | |||
| Operating Income | 21.96% | -10.64% | |||
| Income Before Tax | 27.08% | 28.94% | |||
| Income Tax Expenses | -113.01% | 214.96% | |||
| Earnings from Continuing Operations | 27.33% | 28.61% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 10.53% | -5.00% | |||
| Net Income | 27.34% | 28.61% | |||
| EBIT | 21.96% | -10.64% | |||
| EBITDA | 23.33% | -11.23% | |||
| EPS Basic | 31.86% | 31.45% | |||
| Normalized Basic EPS | 31.59% | 31.76% | |||
| EPS Diluted | 31.86% | 31.45% | |||
| Normalized Diluted EPS | 31.59% | 31.76% | |||
| Average Basic Shares Outstanding | 6.57% | 4.11% | |||
| Average Diluted Shares Outstanding | 6.57% | 4.11% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||